How much funding has Abivax SA raised?

Abivax SA has raised $1.6B in total funding, most recently a Corporate Round.

Who are Abivax SA's investors?

Abivax SA's investors include TCGX, Sofinnova Partners.

Where is Abivax SA headquartered?

Abivax SA is headquartered in Paris, France.

What industry is Abivax SA in?

Abivax SA operates in Biotech, Healthcare.

How many employees does Abivax SA have?

Abivax SA has 51-200 employees.

Abivax SA

IPO

Abivax | Official Website

Public · Paris, France · Founded 2013 · $1.6B raised

Biotech

Healthcare

Headquarters: Paris
Employees: 51–200
Founded: 2013
Business Model: B2B
Website: abivax.com

Total Funding: $1.6B
Last Round: $747.5M Corporate RoundJan 2025
Rounds: 5
Type: Public

About

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is an investigational orally administered once-daily small-molecule compound that enhances the expression of miR-124, a naturally occurring microRNA that plays a critical role in regulating the immune response. Obefazimod is currently in Phase 3 clinical trials (ABTECT program) for the treatment of moderately to severely active ulcerative colitis, with additional clinical programs in Crohn's disease and other inflammatory conditions. Abivax is listed on Nasdaq (ABVX) and Euronext Paris.

Summary

Abivax SA is a Biotech company based in Paris, France, founded in 2013. It has raised $1.6B in total across 5 rounds, most recently a $747.5M Corporate Round round in Jan 2025. Investors include TCGX and Sofinnova Partners.

LinkedIn X (Twitter)